Friday, August 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Bausch Health Cos Stock: Surging on Power Shift and Strong Earnings

Robert Sasse by Robert Sasse
August 15, 2025
in Stocks
0
Bausch Health Cos Stock
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

Bausch Health Cos’ stock soared 11.3% following a dramatic boardroom shakeup, as a major investment firm significantly expanded its stake, becoming the dominant shareholder with a 19.13% holding. The move comes after the firm acquired 34.7 million shares from a departing activist investor group, triggering the automatic termination of a prior board agreement and the resignation of two directors. The new controlling shareholder, already serving as board chairman, expressed strong confidence in the company’s value potential, bolstered by impressive quarterly results. Bausch Health reported adjusted earnings of $0.40 per share, far exceeding analyst estimates of $0.04, while revenue climbed 5% to $2.53 billion. The stock had already surged over 30% last week, reflecting renewed investor optimism.

Long-Term Recovery in Focus

The departing investor group had initially bet on a turnaround but exited after years of lackluster performance. Despite the stock trading below the new majority shareholder’s acquisition price, market sentiment remains positive. The firm highlighted the growth prospects of Bausch Health’s subsidiary as a key driver for future value. With a market capitalization of $2.77 billion, the company still faces challenges, but the massive stake acquisition signals a potential inflection point.

Ad

Bausch Health Cos Stock: Buy or Sell?! New Bausch Health Cos Analysis from August 7 delivers the answer:

The latest Bausch Health Cos figures speak for themselves: Urgent action needed for Bausch Health Cos investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 7.

Bausch Health Cos: Buy or sell? Read more here...

Tags: Bausch Health Cos
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Unitedhealth Stock

Unitedhealth Stock: Buffett's Bet Sparks 12% Surge

Thyssenkrupp Stock

Thyssenkrupp Stock: Plunges Amid Grim Outlook

Berkshire Hathaway Stock

Berkshire Hathaway Stock: Buffett's Bet Divides Loyalists

Recommended

Palantir Stock

Palantir Shares Face Valuation Pressures Despite Strong Earnings

9 months ago
BridgeBio Pharma Stock

BridgeBio Pharma Investors Await Critical Heart Drug Data

9 months ago
Ocugen Stock

Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing

1 month ago
Airbnb Stock

Navigating Regulatory Headwinds and Innovation: Airbnb’s Strategic Crossroads

10 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

MSCI World ETF: Index Provider Rewrites the Rulebook for Fast-Moving Stocks

Airbus’ Paradox: A Slightly Smaller Forecast That Nobody Seems to Mind

Almonty Industries Rebounds From Index-Driven Exit as Tungsten Calculus Shifts Westward

OHB’s Two-Faced Half-Year: Record Orders Mask a Profit Squeeze That Spooked the Market

Trending

Nel ASA Stock
Analysis

Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding

by Jackson Burston
August 7, 2026
0

The Norwegian electrolyser maker Nel ASA is living a split-screen reality. Its order intake just exploded by...

SANDISK Stock

SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market

August 7, 2026
Bitcoin Stock

Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

August 7, 2026
Kioxia Stock

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

August 7, 2026
FALLBACK Stock

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

August 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding
  • SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market
  • Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com